BRPI0720220A2 - Derivados de quinolinas antibacterianos - Google Patents

Derivados de quinolinas antibacterianos

Info

Publication number
BRPI0720220A2
BRPI0720220A2 BRPI0720220-2A2A BRPI0720220A BRPI0720220A2 BR PI0720220 A2 BRPI0720220 A2 BR PI0720220A2 BR PI0720220 A BRPI0720220 A BR PI0720220A BR PI0720220 A2 BRPI0720220 A2 BR PI0720220A2
Authority
BR
Brazil
Prior art keywords
quinolins
antibacterial
derivatives
quinolins derivatives
antibacterial quinolins
Prior art date
Application number
BRPI0720220-2A2A
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
David Francis Alain Lancois
Ismet Dorange
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720220(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0720220A2 publication Critical patent/BRPI0720220A2/pt
Publication of BRPI0720220B1 publication Critical patent/BRPI0720220B1/pt
Publication of BRPI0720220B8 publication Critical patent/BRPI0720220B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
BRPI0720220A 2006-12-06 2007-12-04 derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo BRPI0720220B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06
PCT/EP2007/063313 WO2008068267A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (3)

Publication Number Publication Date
BRPI0720220A2 true BRPI0720220A2 (pt) 2013-12-24
BRPI0720220B1 BRPI0720220B1 (pt) 2020-06-09
BRPI0720220B8 BRPI0720220B8 (pt) 2021-05-25

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720220A BRPI0720220B8 (pt) 2006-12-06 2007-12-04 derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo

Country Status (32)

Country Link
US (1) US8415475B2 (pt)
EP (1) EP2099758B1 (pt)
JP (1) JP5466011B2 (pt)
KR (1) KR101490222B1 (pt)
CN (2) CN101553470A (pt)
AP (1) AP2479A (pt)
AR (1) AR064151A1 (pt)
AU (1) AU2007328887B2 (pt)
BR (1) BRPI0720220B8 (pt)
CA (1) CA2669819C (pt)
CL (1) CL2007003514A1 (pt)
CY (1) CY1117766T1 (pt)
DK (1) DK2099758T3 (pt)
EA (1) EA016733B1 (pt)
ES (1) ES2573689T3 (pt)
HR (1) HRP20160585T1 (pt)
HU (1) HUE028769T2 (pt)
IL (1) IL199083A (pt)
JO (1) JO3271B1 (pt)
ME (1) ME02498B (pt)
MX (1) MX2009005978A (pt)
MY (1) MY181645A (pt)
NO (1) NO341983B1 (pt)
NZ (1) NZ576823A (pt)
PL (1) PL2099758T3 (pt)
PT (1) PT2099758E (pt)
RS (1) RS54794B1 (pt)
SI (1) SI2099758T1 (pt)
TW (1) TWI406659B (pt)
UA (1) UA100972C2 (pt)
WO (1) WO2008068267A1 (pt)
ZA (1) ZA200903950B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2869453C (en) 2012-04-27 2021-03-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
JP6362235B2 (ja) * 2014-07-14 2018-07-25 ツーセン ファーマシューティカル カンパニー リミテッド ピリジン誘導体およびその抗マイコバクテリウムにおける使用
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
LT3250182T (lt) * 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
ES2934785T3 (es) * 2016-03-07 2023-02-27 Global Alliance For Tb Drug Development Inc Compuestos antibacterianos y usos de los mismos
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
KR20200115597A (ko) * 2018-01-29 2020-10-07 카딜라 핼쓰캐어 리미티드 항세균제로서 유용한 헤테로사이클릭 화합물
JP2023547108A (ja) * 2020-10-22 2023-11-09 ルネラ・バイオテック・インコーポレーテッド γサブユニットを標的とするミトコンドリアATP阻害剤は転移を予防する
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
DK1527050T3 (da) * 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
EA011277B1 (ru) * 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
AP2188A (en) 2004-01-23 2010-12-14 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors.
EA011572B9 (ru) 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
RS56357B1 (sr) 2004-09-28 2017-12-29 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
NO20092542L (no) 2009-08-25
AP2479A (en) 2012-09-27
JP5466011B2 (ja) 2014-04-09
SI2099758T1 (sl) 2016-07-29
PL2099758T3 (pl) 2016-08-31
UA100972C2 (ru) 2013-02-25
CA2669819A1 (en) 2008-06-12
TWI406659B (zh) 2013-09-01
EP2099758B1 (en) 2016-03-09
CN104744361B (zh) 2021-06-08
EA016733B1 (ru) 2012-07-30
CY1117766T1 (el) 2017-05-17
IL199083A (en) 2014-08-31
CN101553470A (zh) 2009-10-07
BRPI0720220B8 (pt) 2021-05-25
CN104744361A (zh) 2015-07-01
ZA200903950B (en) 2010-08-25
HRP20160585T1 (hr) 2016-06-17
EA200970535A1 (ru) 2009-10-30
NZ576823A (en) 2012-01-12
NO341983B1 (no) 2018-03-05
EP2099758A1 (en) 2009-09-16
US20100048566A1 (en) 2010-02-25
MX2009005978A (es) 2009-06-16
AR064151A1 (es) 2009-03-18
HK1208437A1 (en) 2016-03-04
RS54794B1 (sr) 2016-10-31
AP2009004874A0 (en) 2009-06-30
BRPI0720220B1 (pt) 2020-06-09
AU2007328887A1 (en) 2008-06-12
HUE028769T2 (en) 2017-01-30
ES2573689T3 (es) 2016-06-09
PT2099758E (pt) 2016-06-02
TW200838528A (en) 2008-10-01
KR101490222B1 (ko) 2015-02-05
WO2008068267A1 (en) 2008-06-12
US8415475B2 (en) 2013-04-09
JP2010511668A (ja) 2010-04-15
MY181645A (en) 2020-12-30
JO3271B1 (ar) 2018-09-16
KR20090086604A (ko) 2009-08-13
IL199083A0 (en) 2010-03-28
ME02498B (me) 2017-02-20
DK2099758T3 (en) 2016-06-13
AU2007328887B2 (en) 2013-01-17
CA2669819C (en) 2016-08-30
CL2007003514A1 (es) 2008-07-11

Similar Documents

Publication Publication Date Title
BRPI0720220A2 (pt) Derivados de quinolinas antibacterianos
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
BRPI0812155A2 (pt) derivados de espiroindolinona
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
BRPI0817935A2 (pt) Derivados de biarila
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
EP2072519A4 (en) DIARYLKETIMINDERIVAT
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
DK2099762T3 (da) Antibakterielle quinolinderivater
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol
ATE509915T1 (de) Antibakterielle chinolinderivate
BRPI0811214A2 (pt) Derivados de pirazolona
BRPI0816705A2 (pt) Derivatido de 6-pirimidinil-pirimid-2-ona
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
BRPI0812827A2 (pt) Derivados de macrolactona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2804 DE 01-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.